Session » (1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 1365

Extraglandular Involvement and Autoantibody Status as Risk Factors for Cardiovascular Disease in Primary Sjogren’s Syndrome (pSS): A 20 Year-follow up Study

Abstract Number: 1366

A Unique Cluster of Inflammatory Monocytes and Functionally Intact Regulatory T Cells in Rare Childhood Sjögren’s Disease

Abstract Number: 1367

Novel Autoantibodies Might Circumvent the Need for Labial Biopsy in a Subset of Seronegative Sjögren’s Disease Patients

Abstract Number: 1368

Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s

Abstract Number: 1369

Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren’s Disease: Results from a Multinational, Real-World Survey

Abstract Number: 1370

Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration

Abstract Number: 1371

Are Ultrasound Salivary Parenchymal Abnormalities More Severe in Primary Sjögren Patients with a Higher Disease Duration ? A Cross-sectional International Study

Abstract Number: 1372

Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab

Abstract Number: 1373

Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome

Abstract Number: 1374

Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival

Abstract Number: 1375

The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome

Abstract Number: 1376

SJOGRENSER Registry: Prospective Evaluation of a Cohort of Patients with Primary Sjögren’s Syndrome After 8 Years of Follow-up

Abstract Number: 1377

Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study

Abstract Number: 1378

The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study

Abstract Number: 1379

Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome

Abstract Number: 1380

Synergistic Dose Effects of Extra X Chromosome in Development of Sjogren’s Syndrome in Klinefelter and Triple X Syndromes

Abstract Number: 1381

Fatigue and Associated Factors in Patients with Primary Sjogren’s Syndrome Compared to Secondary Sjogren’s Syndrome

Abstract Number: 1382

Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.